Is dapostat already on the market in the country? What is the status of its approval for listing?
As of2025, the original drug of daprodustat (Daprodustat) has not yet been approved for marketing in the Chinese market. Therefore, patients currently cannot purchase the drug through formal channels in the country. The drug is still in the approval process, has not yet been included in medical insurance, and there is no clear market pricing.
Daprostat is an oral HIF-PHI (hypoxia-inducible factor- hydroxylase inhibitor), mainly used to treat anemia caused by chronic kidney disease. Due to its unique pharmacological mechanism, daprostat is expected to provide a new option for traditional anemia treatment, especially for dialysis-dependent patients.

Although it has not yet been launched in China, daprostat has been widely used in overseas markets. In the United States and Europe, original drugs have been approved and sold through formal channels. Common specifications are 1mg*30 tablets, 2mg*30 tablets, etc. The price per box is usually between 100 and 500 US dollars. The specific price will vary according to the region and sales channel. Prices in overseas markets are relatively expensive, so some patients may choose to purchase generic drugs to reduce treatment costs.
Currently, generic versions of daprostat are also on the market, the most famous of which is the generic version produced by Lucius Pharmaceuticals in Laos. The specification of this generic drug is 1mg*100 tablets per box, and the price is about 400 RMB. Although the price of generic drugs is relatively low, their efficacy is basically the same as that of the original drugs, and they can still provide effective treatment for patients.
In short, although daprostat has not yet been launched in the Chinese market, there are original drugs and generic drugs overseas for patients to choose from, and the prices also vary depending on the source and specifications of the drug. It is hoped that as the drug approval process progresses, the drug will be launched on the Chinese market in the future and provide treatment options for more patients.
Reference materials:https://en.wikipedia.org/wiki/Daprodustat
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)